PT -期刊文章盟邦尼Breining盟——特丽莎拉拉盟Kyrana Tsapkini AU - Eleni Peristeri盟——玛利亚玛卡瑞娜马丁内斯Cuitino AU -尼法昆盟Argye Hillis TI -跨文化有效评估的对象语义(P6.226) DP - 2014 Apr 08年TA -神经病学PG - P6.226 VI - 82 IP - 10补充4099 - //www.ez-admanager.com/content/82/10_Supplement/P6.226.short 4100 - http:/首页/www.ez-admanager.com/content/82/10_Supplement/P6.226.full所以Neurology2014 Apr 08年;82 AB -目的:评估跨文化fifteen-item了解协会的有效性评估的对象语义。背景:目前,非语言的语义知识测试识别semantic-variant原发性进行性失语(svPPA)对于跨文化的使用是不够的。例如,广泛使用的金字塔和棕榈树测试(PPT)(霍华德,帕特森,1992年,皮尔森公司)包括项目需要文化特定定义特征的知识,而不是知识。这项研究有助于填补临床缺口。我们之前表现出15个PPT美国个人svPPA有别于其他PPA变异和与前颞叶萎缩。我们测试这个跨文化形式的有效性。设计/方法:被52-item PPT在阿根廷43 - 80岁健康对照组(N = 20)、希腊(N = 12)和美国(N = 18)。我们分别取得了15项的繁体汉字和短小精悍的——一个子集的繁体汉字依赖对象的定义特征的知识。 Additionally, 29 svPPA patients were administered the short-form to determine the most accurate cut-off distinguishing svPPA patients vs. all 50 controls using Receiver Operating Curve statistics. RESULTS: A score of <13 on the short-form accurately classified 100% of svPPA vs. controls (specificity 100%; sensitivity 46%). A score of <14 had a specificity of 96% and sensitivity of 73% (AUC=.898; p<0.0001). Across sites, controls’ short-form scores were near perfect (mean=14.9, SD=0.45, range=13-15), while full-form scores varied more widely (mean=49.2, SD=2.27, range=44-52). 6/20 Argentinian, 7/12 Greek, and 5/18 American controls scored outside the published normal range (49-52). Control performance was significantly more frequently classified as normal on the short-form (蠅13/15) vs. the full (蠅49/52) (χ2=32.84, p<0.001). CONCLUSIONS: Control participants from Argentina, Greece, and USA performed near ceiling on the short-form PPT, even while scoring outside the published norms on the full-form. This short-form can be used cross-culturally to assess object semantics. It is also faster to administer while accurately identifying svPPA patients. Study Supported by: RO1 DC011317Disclosure: Dr. Breining has nothing to disclose. Dr. Lala has nothing to disclose. Dr. Tsapkini has nothing to disclose. Dr. Peristeri has nothing to disclose. Dr. Martínez Cuitiño has nothing to disclose. Dr. Manes has nothing to disclose. Dr. Hillis has received research support from Allon Pharmaceutical.Thursday, May 1 2014, 7:30 am-11:00 am